Fanxiu Xiong

Systematic Review

Diabetes and Incidence of Breast Cancer and its Molecular Subtypes: A Systematic Review and Meta-Analysis

- 3 Short title: Diabetes and breast cancer risk
- 4

5 Fanxiu Xiong¹, Qichen Dai², Sihan Zhang³, Stephen Bent^{1,4}, Peggy Tahir⁵, Erin L. Van

Blarigan^{1,6}, Stacey A. Kenfield^{1,6}, June M. Chan^{1,6}, Gabriela Schmajuk⁷, Rebecca E.
 Graff^{1.a}

8

¹ Department of Epidemiology and Biostatistics, University of California, San Francisco,
 San Francisco, CA, USA

- ² Department of Breast Surgery, National Cancer Center/Cancer Hospital, Chinese
- 12 Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- ³ Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University
 of Science and Technology, Wuhan, China.

⁴Department of Psychiatry, University of California, San Francisco, San Francisco, CA,
 USA.

- ⁵UCSF Library, University of California, San Francisco, San Francisco, CA, USA
- ⁶Department of Urology, University of California, San Francisco, San Francisco, CA,
- 19 USA.
- ⁷Division of Rheumatology, Department of Medicine, University of California, San
- 21 Francisco, San Francisco, CA, USA.
- 22
- 23 ^a Corresponding Author:
- 24 Rebecca E Graff, ScD
- 25 Department of Epidemiology and Biostatistics
- 26 University of California, San Francisco, School of Medicine
- 27 San Francisco, CA 94143
- 28 E-mail: <u>Rebecca.Graff@ucsf.edu</u>
- 29

30 ACKNOWLEDGEMENTS

31 We gratefully acknowledge Dr. Chiung-Yu Huang and Dr. Thomas Newman for their

- 32 critical feedback.
- 33

34 FUNDING

- 35 JMC receives funding from the Cancer League Foundation. REG is supported by a
- 36 Young Investigator Award from the Prostate Cancer Foundation.
- 37

38 **COMPETING INTERESTS**

- 39 JMC declares that her husband is a full-time employee of Adela, Inc. and a prior
- 40 employee of GRAIL (within the past three years).
- 41

Fanxiu Xiong

Systematic Review

42 AUTHOR CONTRIBUTIONS

43 FX, GS, and REG conceived and designed the study. FX, SB, PT, GS, and REG

44 developed the methods. FX, QD, SZ reviewed and extracted the data and performed

the quality rating of studies. FX, SB, ELV, SAK, JMC, and REG interpreted the results.

- 46 FX and REG wrote the initial draft of the manuscript. GS and REG supervised this
- 47 study. All authors revised it for critically important content and read and gave approval
- 48 of the final version.
- 49

51

50 WORD COUNTS

- 1) Abstract: 303
- 2) Main text (excluding references and legends): 3559
- 52 53

54 TOTAL NUMBER OF EACH

- 1) References: 47 for main text and 72 for tables
- 56 2) Tables: 2
- 57 3) Figures: 3

Fanxiu Xiong

Systematic Review

58 Abstract

| 59 | Diabetes mellitus (DM) has been proposed to be positively associated with breast |
|----|---|
| 60 | cancer (BCa) risk due to shared risk factors, metabolic dysfunction, and use of |
| 61 | antidiabetic medications. We conducted a systematic review and meta-analysis to |
| 62 | evaluate the association between DM and BCa risk. We searched PubMed, Embase, |
| 63 | and Web of Science for cohort and case-control studies assessing the association |
| 64 | between DM and BCa published before December 10, 2021. Two reviewers |
| 65 | independently screened the studies for inclusion, abstracted article data, and rated |
| 66 | study quality. Random effects models were used to estimate summary risk ratios (RRs) |
| 67 | and 95% confidence intervals (CIs). From 8396 articles identified in the initial search, 70 |
| 68 | independent studies were included in the meta-analysis. DM was associated with an |
| 69 | overall increased risk of BCa (RR=1.20, 95% CI: 1.11-1.29). The 24 case-control |
| 70 | studies demonstrated a stronger association (RR=1.26, 95% CI: 1.13-1.40) than the 46 |
| 71 | cohort studies (RR=1.15, 95% CI: 1.05-1.27). Studies reporting risk by menopausal |
| 72 | status found that postmenopausal women had an elevated risk of developing BCa |
| 73 | (RR=1.12, 95% CI: 1.07-1.17). No association between DM and BCa risk was observed |
| 74 | among premenopausal women (RR=0.95, 95% CI: 0.85-1.05). In addition, DM was |
| 75 | associated with significantly increased risks of estrogen receptor (ER)+ (RR=1.09, 95% |
| 76 | CI: 1.00-1.20), ER- (RR=1.16, 95% CI: 1.04-1.30), and triple negative BCa (RR=1.41, |
| 77 | 95% CI: 1.01-1.96). The association estimate for human epidermal growth factor 2- |
| 78 | positive BCa was also positive (RR=1.21, 95% CI: 0.52-2.82), but the confidence |
| 79 | interval was wide and crossed the null. Our meta-analysis confirms a modest positive |
| 80 | association between DM and BCa risk. In addition, our results suggest that the DM and |

Fanxiu Xiong

- 81 BCa association may be modified by menopausal status, and DM may be differentially
- 82 associated with BCa subtypes defined by receptor status. Additional studies are
- 83 warranted to investigate the mechanisms underlying these associations and any
- 84 influence of DM on BCa receptor expression.
- 85 **KEYWORDS:** Diabetes; breast cancer; molecular subtypes; menopausal status; body
- 86 mass index

Fanxiu Xiong

Systematic Review

87 1 INTRODUCTION

88 Among women worldwide, breast cancer (BCa) is the most prevalent malignancy and 89 the leading cause of cancer-related death[1]. In 2020, there were an estimated 2.3 90 million new cases of female BCa and more than half a million deaths from disease[2]. 91 Obesity is an established risk factor for BCa, particularly in postmenopausal women[3]. 92 Given the relationship between obesity and BCa, it stands to reason that varying 93 metabolic abnormalities could be associated with BCa risk. Diabetes mellitus (DM) is 94 one of the most common metabolic abnormalities globally, such that 463 million people 95 were living with DM in 2019[4]. DM and its complications increase the risk of 96 cardiovascular disease, neuropathy, retinopathy, kidney failure, and overall mortality[5], 97 but its relationship with BCa has not been firmly established.

98 Due to shared risk factors, metabolic dysfunction in diabetic patients, and 99 antidiabetic medication use, it has been proposed that DM could be positively 100 associated with subsequent BCa risk[6]. Indeed, the potential role of DM in BCa 101 incidence has been widely investigated. The largest existing meta-analysis, which was 102 published in 2012 and included 40 observational studies, indicated a 20% excess risk of 103 BCa among women with DM[7]. Heterogeneity among studies included in this meta-104 analysis was substantial, and studies published since have yielded inconsistent 105 findings. In addition, studies investigating associations between DM and specific BCa 106 molecular subtypes have been inconclusive. Given that BCa is a heterogeneous 107 disease – often grouped according to joint expression of hormonal and growth 108 receptors, including estrogen receptor (ER), progesterone receptor (PR), and human

Fanxiu Xiong

Systematic Review

- 109 epidermal growth factor receptor 2 (HER2)[8] it is important to consider possible
- 110 distinctions in metabolic etiology.
- 111 A solidified understanding of the relationship between DM and the risk of BCa
- and its subtypes is important for clarifying BCa etiology and informing screening
- decisions. Therefore, we reviewed and synthesized the findings from relevant
- epidemiologic studies to achieve summary estimates for associations between DM and
- risk of BCa overall and of BCa defined by receptor expression.

116 2 MATERIALS AND METHODS

117 2.1 Research question

- 118 Toward the formulation of a coherent research question, we implemented the
- 119 Population, Interventions or Exposure, Comparator, Outcome, Study Design (PICOS)

120 approach, as suggested by PRISMA guidelines.

- 121
- 122 Population
- 123 Women aged 18 years or older.
- 124
- 125 Exposure
- 126 DM identified prior to any detection of BCa. Gestational DM, which only occurs during
- 127 pregnancy, was not included.
- 128
- 129 Comparison
- 130 Lacking a diagnosis of DM prior to any detection of BCa.

Fanxiu Xiong

Systematic Review

- 132 Outcome
- 133 Malignant BCa, identified by self-report or from medical records.

134

135 Study Design

136 For our primary analyses, cohort and case-control studies were included. To assess

- 137 associations between DM and BCa molecular subtypes, all other study designs were
- 138 considered.

139 2.2 Literature search

140 This systematic review and meta-analysis was conducted according to the Preferred

141 Reporting Item for Systematic Reviews and Meta-analysis 2020 (PRISMA 2020)

142 statement[9]. The protocol was registered in the International Prospective Register of

143 Systematic Reviews (PROSPERO CRD42022311936).

144 We conducted a comprehensive database search regarding DM and BCa risk in 145 PubMed (National Library of Medicine), Embase (Elsevier), and Web of Science 146 (Clarivate Analytics). We focused on three main concepts: diabetes, BCa, and 147 associated risks and incidence. Appropriate synonyms were developed for each 148 concept, and we used both keywords and index terms (e.g., Mesh, Emtree) appropriate 149 to each database. Full search strategies are included in the Search Appendix. Human 150 studies that were published by Dec 10, 2021 and written in English were included. We 151 also reviewed the reference section of studies included in previously published 152 systematic reviews regarding DM and BCa to identify additional studies that met the 153 eligibility criteria[7,10–14].

Fanxiu Xiong

Systematic Review

154 2.3 Study selection

- 155 Titles and abstracts were independently screened by two reviewers (FX and QD) to
- identify potentially relevant epidemiologic studies. Full texts of potentially relevant
- 157 articles were retrieved and reviewed according to inclusion (PICOS) and exclusion
- 158 criteria (below). Disagreements that were not resolved by discussion between the two
- reviewers were adjudicated by a third reviewer (SZ).
- 160 Studies were excluded if: they did not differentiate between benign and malignant
- breast tumors; DM was diagnosed at the same time as or after BCa diagnosis; the
- 162 number of BCa cases in cohort studies or DM cases in case-control studies was less
- than 10; they were not human studies; they were not written in English; or they were
- 164 case reports, review articles, meeting abstracts, or letters. When more than one study
- 165 was conducted in the same study population, only the most recent findings were
- included.

167 2.4 Data abstraction and quality assessment

168 Two reviewers (FX and SZ) independently abstracted data from relevant articles using a 169 standardized form. Discrepancies were resolved by discussion with a third reviewer 170 (QD). Abstracted information included: first author, year of publication, study population, 171 study design, country of study, age range, follow-up length or calendar period, DM assessment method, DM classification (i.e., any DM, type 1 DM (T1D), and/or type 2 172 173 DM (T2D)), BCa assessment method, BCa molecular subtypes, covariates, risk 174 estimates with corresponding 95% confidence intervals (CIs), and any association 175 measures within subgroups. Only estimates from fully-adjusted models were abstracted.

Fanxiu Xiong

Systematic Review

176 The Newcastle-Ottawa-Scale (NOS) was employed to evaluate the risk of bias in 177 selected cohort and case-control studies[15]. Briefly, the NOS consists of eight items 178 and is categorized into three domains: 1) selection of study population (4 items): 2) level 179 of comparability between the study groups (1 item); and 3) assessment of exposure for 180 case-control studies or outcome for cohort studies (3 items). One star could be awarded 181 for each item, with the exception of a possible two stars for the single comparability 182 item. Studies with stars of 8-9, 6-7, and 1-5 were deemed high-, medium-, and low-183 quality, respectively.

184 2.5 Statistical analysis

185 If risk ratios (RRs) were not reported in contributing studies, we assumed that other risk 186 measures, such as odds ratios (ORs) and hazard ratios (HRs), numerically 187 approximated RRs under the rare disease assumption[16]. When contributing studies only reported subgroup estimates (e.g., separate estimates for pre- and post-188 189 menopausal women), we calculated summary estimates for these individual studies 190 before including them in our meta-analysis. To do so, we used fixed effects models 191 when heterogeneity between subgroups was not significant and random effects models 192 when heterogeneity was significant (P < 0.05).

For our meta-analysis, we estimated summary RRs and 95% CIs using random effects models, to allow for differences in study populations and generate conservative results. Heterogeneity across studies was assessed using 1) the I^2 statistic, with 0-25%, 25-75%, and >75% representing possibly unimportant, moderate, and substantial heterogeneity, respectively, and 2) Cochran's Q statistic, with P < 0.05 as the threshold for statistical significance. Leave-one-out sensitivity analyses were carried out to

Fanxiu Xiong

Systematic Review

199 evaluate the influence of each study on the overall summary estimate. A temporal 200 cumulative meta-analysis was also performed to show how the overall estimate 201 changed as each study was added in chronological order. We additionally performed 202 analyses stratified by study quality (high, medium, or low). 203 Publication bias was graphically assessed using a funnel plot. Duval and 204 Tweedie's trim-and-fill method was implemented based on the funnel plot to estimate 205 the influence of potentially missing studies on the summary estimate[17]. Begg's test 206 and Egger's test were also implemented to assess publication bias. 207 To explore potential sources of heterogeneity, separate analyses were performed 208 by study design (cohort study or case-control study), study region (Asia, Americas, 209 Europe, or Australia), year of publication (before or after the largest existing review, 210 published in 2012)[10], method of DM ascertainment (self-report or medical review),

adjustment for body mass index (BMI; no or yes), and adjustment for parity (no or yes).

212 Meta-regression analyses stratified by the aforementioned subgroups were then

213 performed to examine differences.

214 Some studies performed separate analyses in pre- and post-menopausal 215 women. We used random-effects models to estimate the association of DM with pre-216 and post-menopausal BCa separately. If no information regarding menopausal status 217 was provided, we defined postmenopausal to be age 50 years or older[18]. In addition, 218 we examined associations between DM and BCa molecular subtypes. The subtypes 219 were grouped into four categories: ER-positive (ER+; regardless of PR/HER2 status), 220 ER-negative (ER-; regardless of PR/HER2 status), HER2-positive (HER2+; negative 221 ER/PR), and triple-negative (TN; negative ER/PR/ HER2)[19].

Fanxiu Xiong

Systematic Review

| 222 | Hypothesis tests were 2-sided (unless otherwise specified) with a significance |
|-----|--|
| 223 | threshold of 0.05. Statistical analyses were performed using Comprehensive Meta- |
| 224 | Analysis Version 3 (Biostat, Englewood, NJ 2013) and R Version 4.0.2. |

225

226 **3 RESULTS**

227 3.1 Literature search

228 Initial searches of the databases yielded 10,773 publications. Assessment of references

in relevant reviews[7,10–14] yielded an additional 404 publications. After removing

230 duplicates and article types other than research articles, 3,893 publications remained.

After removing papers on the basis of title (n=3,150) or abstract (n=488) and excluding

reports (n = 23) which were inaccessible online, were conference abstracts with no full

text, or had titles or abstracts that do not correspond to those indexed by the search

databases, the full text of 232 reports that could be retrieved were reviewed. 70 studies

that met eligibility criteria were included in this review and meta-analysis. 2 additional

236 cross-sectional studies assessing molecular subtypes at the time of BCa diagnosis were

included in the review but not the meta-analysis. Figure 1 shows the PRISMA flowchartfor the study selection process.

239 3.2 Study description and quality assessment

Descriptive data for the selected studies are presented in Table 1. Of the 72 included studies, 46 were cohort studies, 24 were case-control studies, and the other 2 were cross-sectional studies evaluating BCa molecular subtypes. 24 studies were conducted in Asia, 24 were conducted in the Americas, 21 were conducted in Europe, and 3 were

Fanxiu Xiong

Systematic Review

| 253 | 3.3 Meta-analysis results |
|-----|--|
| 252 | rated due to their cross-sectional design. |
| 251 | studies. The 2 studies that specifically investigated BCa molecular subtypes were not |
| 250 | studies were deemed medium to high quality, including 34 cohort and 18 case-control |
| 249 | for age, 36 adjusted for BMI, and 24 adjusted for menopausal status. 52 out of 70 rated |
| 248 | studies, BCa was identified from clinical or cancer registry records. All studies adjusted |
| 247 | identification (n=4). 10 studies differentiated T1D from T2D. With the exception of 5 |
| 246 | reports (n=39), with some studies adopting a combination of self-report and clinical |
| 245 | 10,827,079 participants. The slim majority of studies assessed DM based on medical |
| 244 | conducted in Australia. Population sizes varied substantially, ranging from 110 to |

254 2 studies were not included in the meta-analysis because they were cross-sectional and

only assessed molecular subtypes at the time of BCa diagnosis. The meta-analysis of

256 70 studies evaluating the association between DM and BCa risk overall demonstrated a

257 20% increased risk of BCa among women with DM (RR=1.20, 95% CI: 1.11-1.29;

Figure 2). Heterogeneity among the studies was substantial (l²=97.9%, P-

259 heterogeneity<0.001). Leave-one-out sensitivity analyses revealed that the findings

from Dankner 2016[20] were especially influential; excluding this study produced the

261 most attenuated summary estimate (RR=1.14, 95% CI: 1.09-1.19, I²=88.7%, P-

heterogeneity<0.001; Supplementary Figure S1). The temporal cumulative meta-

analysis demonstrated that the summary estimate reached statistical significance in

264 2001 and remained fairly constant and significant after 2005 (Supplementary Figure S2).

265 Meta-analysis of the 9 high-quality (RR=1.12, 95% CI: 1.02-1.22, I²=53.0%, P-

heterogeneity=0.03; Table 2) and, separately, 45 medium-quality (RR=1.15, 95% CI:

Fanxiu Xiong

Systematic Review

| 267 | 1.05-1.27, I ² =98.4%, P-heterogeneity<0.001) studies yielded slightly attenuated |
|-----|--|
| 268 | summary estimates. The summary RR for the 16 low-quality studies was 1.42 (95% CI: |
| 269 | 1.08-1.86, I ² =96.6%, P-heterogeneity<0.001). |
| 270 | Slight publication bias was detected by the funnel plot (Supplementary Figure |
| 271 | S3A) and Begg's test (1-tailed P<0.001), but not by Egger's test (1-tailed P=0.11). |
| 272 | When using trim and fill analysis to measure publication bias, no studies were |
| 273 | hypothetically missing, and the summary estimate was therefore unchanged. |
| 274 | The results for subgroup analyses are presented in Table 2. The association |
| 275 | estimate summarizing the 46 cohort studies remained statistically significant (RR=1.15, |
| 276 | 95% CI: 1.05-1.27), despite 28 studies having reported null findings. The heterogeneity |
| 277 | among cohort studies was still considerable (I^2 =98.6%, P-heterogeneity <0.001), but no |
| 278 | publication bias was found by the funnel plot or Egger's test (1-tailed P=0.11). Begg's |
| 279 | test did indicate heterogeneity (1-tailed P < 0.001) (Supplementary Figure S3B). Meta- |
| 280 | analysis of the 7 cohort studies of high quality showed more homogeneous results |
| 281 | $(I^2=23.1\%, P-heterogeneity=0.25)$, with only one study demonstrating a significant |
| 282 | association. The summary estimate was not statistically significant (RR=1.06, 95% CI: |
| 283 | 0.99-1.14). |

The 24 case-control studies showed a significantly increased BCa risk among women with DM (RR=1.26, 95% CI: 1.13-1.40), though 14 studies found no association. Case-control studies demonstrated less heterogeneity than cohort studies (I²=73.1%, Pheterogeneity<0.001). However, the funnel plot demonstrated significant asymmetry, wherein nearly all small studies with less than average estimates were missing (Supplementary Figure S3C). After imputing 9 hypothetically missing association

Fanxiu Xiong

Systematic Review

| 290 | estimates to the bottom left of the funnel plot, the summary estimate decreased |
|-----|--|
| 291 | remarkably and was no longer statistically significant (RR=1.05, 95% CI: 0.93-1.19). |
| 292 | The 2 case-control studies that were deemed high quality reported ORs of 1.40 (95% CI: |
| 293 | 1.00-1.96) and 1.70 (95% CI: 1.15-2.54), respectively. The pooled estimate from 19 |
| 294 | medium- to high-quality case-control studies was 1.17 (95% CI: 1.07-1.29, I^2 =59.8%, P- |
| 295 | heterogeneity<0.001). |

Among regions, the largest association estimate between DM and BCa risk was

297 found in Asia (RR=1.34, 95% CI: 1.11-1.63, I²=99.1%, P-heterogeneity<0.001, n=23),

²⁹⁸ followed by Europe (RR=1.13, 95% CI: 1.06-1.21, I²=83.4%, P-heterogeneity<0.001,

299 n=21), and the Americas (RR=1.10, 95% CI: 1.03-1.17, I²=40.8%, P-heterogeneity=0.02,

n=23). The 3 Australian studies showed homogeneous findings, and though the

301 summary association estimate was comparable to that for European studies, the

302 combined results were not statistically significant (RR=1.15, 95% CI: 0.99-1.33,

 I^2 =32.0%, P-heterogeneity=0.23). Estimates for studies published before 2012

304 (RR=1.18, 95% CI: 1.09-1.26, I²=77.6%, P-heterogeneity<0.001, n=28) versus in/after

305 2012 (RR=1.20, 95% CI: 1.08-1.33, I²=98.7%, P-heterogeneity<0.001, n=42) were

306 essentially comparable. Methods of DM identification did not materially influence

307 association estimates (self-report RR=1.18, 95% CI: 1.09-1.29, I²=62.0%, P-

heterogeneity<0.001, n=30 versus medical records RR=1.14, 95% CI: 1.03-1.26,

³⁰⁹ I²=98.9%, P-heterogeneity<0.001, n=37). Studies that did not adjust for BMI yielded an

310 equivalent summary estimate (RR=1.21, 95% CI: 1.08-1.35, I²=98.9%, P-

heterogeneity<0.001, n=31) to studies controlling for BMI (RR=1.19, 95% CI: 1.06-1.32,

312 I²=89.7%, P-heterogeneity<0.001, n=39). 56 studies not accounting for parity yielded a

Fanxiu Xiong

Systematic Review

| 313 | summary estimate of 1.15 (95% CI: 1.06-1.26, I^2 =98.3%, P-heterogeneity<0.001), while |
|-----|---|
| 314 | the summary estimate of the remaining 14 studies was 1.39 (95% CI: 1.18-1.62, |
| 315 | I^2 =79.7%, P-heterogeneity<0.001). The meta-regressions did not suggest heterogeneity |
| 316 | across any subgroups. |
| 317 | 31 studies, including 11 cohort studies, measured BCa risk in postmenopausal |
| 318 | women, for whom the summary RR was 1.12 (95% CI: 1.07-1.17, I^2 =65.5%, P- |
| 319 | heterogeneity<0.001). 15 studies reported estimates in premenopausal women, and |
| 320 | none of them found significant associations. We also did not observe an overall |
| 321 | association for premenopausal BCa, and the between-study heterogeneity was |
| 322 | negligible (RR=0.95, 95% CI: 0.85-1.05, I ² =0.00%, P-heterogeneity=0.78). |
| 323 | 13 studies (including the two cross-sectional studies that were not included in the |
| 324 | other meta-analyses) evaluated associations with BCa molecular subtypes. All of them |
| 325 | presented results for ER+ BCa, and the summary RR was 1.09 (95% CI: 1.00-1.20, |
| 326 | I ² =52.4%, P-heterogeneity=0.01; Figure 3A). Analysis based on 11 studies showed an |
| 327 | increased risk of ER- BCa associated with DM (RR=1.16, 95% CI: 1.04-1.30, I^2 =0.00%, |
| 328 | P-heterogeneity=0.57; Figure 3B). The summary estimate for 3 studies that reported |
| 329 | data for HER2+ BCa did not reveal a statistically significant association, and the |
| 330 | confidence interval was especially wide (RR=1.21, 95% CI: 0.52-2.82, I ² =67.5%, P- |
| 331 | heterogeneity=0.05; Figure 3C). The 5 studies that assessed the risk of TN BCa |
| 332 | showed a significantly elevated risk related to DM (RR=1.41, 95% CI: 1.01-1.96, |
| 333 | I ² =49.7%, P-heterogeneity=0.09; Figure 3D). |
| | |

334

335 4 DISCUSSION

Fanxiu Xiong

Systematic Review

In this review of evidence regarding a possible association between DM and BCa risk, we observed a positive relationship in many studies, even while more than half of studies reported null results. In the overall meta-analysis including 70 cohort and casecontrol studies, we identified a 20% higher risk of BCa in women with DM. The association was more modest but still statistically significant when restricting to highquality studies.

342 Our findings of increased BCa risk in women with DM align with conclusions from 343 previous reviews[7,10-14]. Wolf et al. (2005) was the first to summarize the 344 association[11]. Their findings based on 6 cohort and 4 case-control studies suggested 345 that T2D, but not T1D, may be associated with 10-20% excess risk of BCa. The reviews 346 and meta-analyses that have been published since have reported similar summary 347 estimates [7,10,12–14]. The largest review, which included 40 observational studies, 348 was conducted by Hardefeldt et al. in 2012. It demonstrated a 20% increased risk of 349 BCa associated with DM[7]. In contrast to our primary analyses, Hardefeldt et al. 350 included cross-sectional studies and gestational DM. We largely focused on cohort and 351 case-control studies in an effort to consider temporality. We did not evaluate gestational 352 DM because its pathogenesis differs from that of other DM, which could render its 353 impact on breast tumorigenesis distinct. A recent meta-analysis assessed the 354 relationship of gestational DM with BCa risk with null results[21,22]. 355 Several biological mechanisms for BCa initiation in diabetic patients have been

postulated. DM is characterized by hyperglycemia and hyperinsulinemia. Regarding the
 former, excessive glucose could favor the selection of malignant cell clones[23] and/or
 induce DNA damage, downregulate the expression of antioxidants[24], and increase the

Fanxiu Xiong

Systematic Review

| 359 | generation of reactive oxygen species[25,26]. Regarding the latter, increased insulin |
|-----|---|
| 360 | levels resulting from resistance to endogenous insulin or insulin treatment could directly |
| 361 | promote BCa cell proliferation and inhibit cell apoptosis or indirectly mediate growth- |
| 362 | promoting actions by increasing hepatic insulin-like growth factor-1 (IGF-1) |
| 363 | production ^{17–19} . The mechanical pathways of fat-induced inflammatory cytokines and |
| 364 | altered levels of sex hormone and sex hormone-binding globulin may also play a |
| 365 | role[27,28]. Preclinical data suggest that use of the first-line antidiabetic therapy |
| 366 | metformin could be beneficial for BCa prevention because it directly suppresses cell |
| 367 | proliferation through the activation of AMPK and regulation of the mTOR signaling |
| 368 | pathway or indirectly improves hyperglycemia, hyperinsulinemia, and inflammation[29- |
| 369 | 31]. However, epidemiologic evidence regarding the relationship between metformin |
| 370 | and BCa prevention has been inconsistent[32]. |
| | |

371 Despite the overall positive association between DM and BCa that we identified, 372 heterogeneity across studies was substantial. Population composition, study design, 373 study region, and covariate adjustment all impacted the findings. In particular, our meta-374 analysis of cohort studies yielded a more modest summary estimate than our meta-375 analysis of case-control studies. Publication bias, however, may not have been 376 negligible among case-control studies, and imputation of potentially missing estimates 377 from individual studies yielded a summary estimate that was attenuated and non-378 significant.

We observed a 34% increased risk of BCa in women with DM in studies conducted in Asia, whereas studies conducted in Western populations demonstrated smaller associations. We note that heterogeneity was highest in the meta-analysis of

Fanxiu Xiong

Systematic Review

| 382 | studies conducted in Asia. To explore heterogeneity among such studies, we ran a |
|-----|---|
| 383 | posteriori meta-regression analyses that demonstrated a significant difference between |
| 384 | studies that did versus did not adjust for BMI. 13 studies that did not adjust for BMI |
| 385 | indicated a significant 53% increased risk of BCa among women with DM, while 10 |
| 386 | studies that did adjust for BMI did not yield a significant summary association. |
| 387 | Though adjustment for BMI was consequential for studies in Asia, BMI-adjusted |
| 388 | studies overall had a comparable summary estimate to studies that did not adjust for |
| 389 | BMI. These results suggest that DM may be a risk factor for BCa independent of obesity. |
| 390 | Nonetheless, obesity and DM might trigger similar pathogenic mechanisms of BCa |
| 391 | development, including metabolic changes, inflammation, insulin resistance and |
| 392 | increased IGF-1, and altered antitumor immunity[33]. Parity, and particularly multiple |
| 393 | pregnancies, has been linked with an increased risk of T2DM but is associated with a |
| 394 | lower risk of BCa[34,35]. Ignoring parity when evaluating the relationship between T2M |
| 395 | and BCa could result in underestimations of the true association. Indeed, we found that |
| 396 | studies that adjusted for parity yielded slightly stronger association estimates. |
| 397 | BCa is a heterogeneous disease with varied molecular features, but the |
| 398 | association between DM and BCa molecular subtypes is uncertain. Biological evidence |
| 399 | suggests that hyperinsulinemia could induce expression and increase the binding ability |
| 400 | of ER[36]. By contrast, metformin may repress the expression of ER and ER target |
| 401 | genes[37]. DM-induced changes in levels of bioavailable sex hormones, such as |
| 402 | increasing levels of estrogen and androgen and decreasing levels of progesterone[36], |
| 403 | could also impact receptor expression. One meta-analysis found non-significant |

404 associations between DM and ER, PR, and HER2 status, respectively, by comparing

Fanxiu Xiong

Systematic Review

hormone receptor negativity to their positive counterparts[38]. In our review, we found
that DM was most strongly associated with TN BCa, which is among the most
aggressive types of disease.

408 We were not able to combine findings regarding associations between DM 409 duration and BCa risk since studies had different DM duration categories. However, 410 multiple, though not all, studies that assessed the temporal trend of the association 411 between DM and BCa indicated that the relationship was strongest during the time 412 period closely following DM diagnosis[39–45]. It is possible that women with newly 413 diagnosed DM have more frequent contact with health care providers and are thus more 414 likely to uncover BCa. Neglecting this detection bias may lead to overestimation of BCa 415 risk at the time of DM diagnosis[46]. However, screening bias is unlikely to account for 416 the excess risk of BCa observed up to 10 years following DM diagnosis[42,45,47,48], 417 suggesting that DM may play a real etiologic role in BCa development.

418 Our review expands upon findings from previous reviews in several important 419 ways. First, we assessed the risk of bias for each study. As such, we were able to 420 combine findings from only high-quality studies, which were least likely to be affected by 421 selection bias, confounding, and reverse causation. Second, we identified and adjusted 422 for potential missingness of case-control studies with small sample sizes and non-423 significant results. Third, our study summarized existing evidence addressing possible 424 associations between DM and molecular subtypes of BCa. Nevertheless, there are 425 some limitations of this review worth noting. Many of the contributing studies were 426 susceptible to selection bias, most often related to restriction to older ages, so as to 427 maximize the number of DM and/or BCa cases. In addition, most studies were unable to

Fanxiu Xiong

Systematic Review

428 differentiate between T1D and T2D. Because T1D and T2D may differ in etiology, 429 patient demographics, and treatment regimens, the pathogenesis of BCa could be 430 different in these two patient groups. It is reasonable to assume that the results of this 431 review largely concern T2D given that more than 95% of DM cases are estimated to be 432 T2D[49], and in many studies, the median/mean age at DM diagnosis was above 40 years. Finally, most included studies did not report information on DM therapy, which 433 434 could mediate any relationship between DM and BCa risk. 435 In conclusion, this updated systematic review and meta-analysis confirms prior 436 findings of an increased risk of BCa in women with DM. In addition, our results suggest 437 that women with DM may have a higher risk of diagnosis with an aggressive molecular 438 subtype of BCa compared to women without DM. Further high-quality evidence is needed to verify the relationship between DM and BCa receptor expression, understand 439 440 the underlying mechanisms of breast carcinogenesis in women with DM, and eventually 441 provide evidence-based recommendations for BCa prevention and treatment.

Fanxiu Xiong

Systematic Review

442 **REFERENCES**

- 1. Breast cancer [Internet]. [cited 2022 May 23]. Available from:
- 444 https://www.who.int/news-room/fact-sheets/detail/breast-cancer

2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global
Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for
36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.

- 3. García-Estévez L, Cortés J, Pérez S, Calvo I, Gallegos I, Moreno-Bueno G. Obesity
- and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by
- 450 Menopausal Status. Front Oncol [Internet]. 2021 [cited 2022 May 23];11. Available from:
- 451 https://www.frontiersin.org/article/10.3389/fonc.2021.705911
- 452 4. Cuadros DF, Li J, Musuka G, Awad SF. Spatial epidemiology of diabetes: Methods
- 453 and insights. World J Diabetes. Pleasanton: Baishideng Publishing Group Inc;
- 454 2021;12:1042–56.
- 455 5. Diabetes [Internet]. [cited 2022 Feb 17]. Available from: https://www.who.int/news456 room/fact-sheets/detail/diabetes
- 457 6. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al.
 458 Diabetes and Cancer: A Consensus Report. CA Cancer J Clin. 2010;60:207–21.

459 7. Hardefeldt PJ, Edirimanne S, Eslick GD. Diabetes increases the risk of breast cancer:
460 a meta-analysis. Endocr Relat Cancer. 2012;19:793–803.

- 8. Dai X, Xiang L, Li T, Bai Z. Cancer Hallmarks, Biomarkers and Breast Cancer
 Molecular Subtypes. J Cancer. 2016;7:1281–94.
- 9. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ.
 2021;n71.
- 466 10. Boyle P, Boniol M, Koechlin A, Robertson C, Valentini F, Coppens K, et al. Diabetes
 467 and breast cancer risk: a meta-analysis. Br J Cancer. 2012;107:1608–17.
- 468 11. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B. Diabetes mellitus and breast469 cancer. :9.
- 470 12. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: A
 471 meta-analysis. Int J Cancer. 2007;121:856–62.
- 13. Liao S, Li J, Wei W, Wang L, Zhang Y, Li J, et al. Association between diabetes
- 473 mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pac J Cancer
 474 Prev APJCP. 2011;12:1061–5.

Fanxiu Xiong

- 14. De Bruijn KMJ, Arends LR, Hansen BE, Leeflang S, Ruiter R, van Eijck CHJ.
- 476 Systematic review and meta-analysis of the association between diabetes mellitus and 477 incidence and mortality in breast and colorectal cancer. Br J Surg. 2013;100:1421–9.
- 478 15. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the
 479 quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.
- 480 16. Symons MJ, Moore DT. Hazard rate ratio and prospective epidemiological studies. J
 481 Clin Epidemiol. 2002;55:893–9.
- 482 17. Duval S, Tweedie R. Trim and Fill: A Simple Funnel-Plot-Based Method of Testing
 483 and Adjusting for Publication Bias in Meta-Analysis. Biometrics. 2000;56:455–63.
- 484 18. Menopause Symptoms and causes Mayo Clinic [Internet]. [cited 2022 May 3].
 485 Available from: https://www.mayoclinic.org/diseases-conditions/menopause/symptoms486 causes/syc-20353397
- 19. Barańska A, Dolar-Szczasny J, Kanadys W, Kinik W, Ceglarska D, Religioni U, et al.
- 488 Oral Contraceptive Use and Breast Cancer Risk According to Molecular Subtypes
- 489 Status: A Systematic Review and Meta-Analysis of Case-Control Studies. Cancers.490 2022;14:574.
- 491 20. Dankner et al. 2016 Time-Dependent Risk of Cancer After a Diabetes Dia.pdf.
- 492 21. Sona MF, Myung S-K, Park K, Jargalsaikhan G. Type 1 diabetes mellitus and risk of 493 cancer: a meta-analysis of observational studies. Jpn J Clin Oncol. 2018;48:426–33.
- 494 22. Wang Y, Yan P, Fu T, Yuan J, Yang G, Liu Y, et al. The association between
 495 gestational diabetes mellitus and cancer in women: A systematic review and meta496 analysis of observational studies. Diabetes Metab. 2020;46:461–71.
- 497 23. Warburg O. On the Origin of Cancer Cells. Science. American Association for the
 498 Advancement of Science; 1956;123:309–14.
- 499 24. Chronic oxidative stress as a mechanism for glucose toxicity of the beta cell in Type
- 2 diabetes | SpringerLink [Internet]. [cited 2021 Jul 23]. Available from:
- 501 https://link.springer.com/article/10.1007%2Fs12013-007-0026-5
- 502 25. Collaboration TERF. Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific
- 503 Death [Internet]. http://dx.doi.org/10.1056/NEJMoa1008862. Massachusetts Medical
- 504 Society; 2011 [cited 2021 Jul 22]. Available from:
- 505 https://www.nejm.org/doi/10.1056/NEJMoa1008862
- 506 26. Jee SH. Fasting Serum Glucose Level and Cancer Risk in Korean Men and507 Women. JAMA. 2005;293:194.
- 508 27. Crave JC, Lejeune H, Brébant C, Baret C, Pugeat M. Differential effects of insulin 509 and insulin-like growth factor I on the production of plasma steroid-binding globulins by

Fanxiu Xiong

- 510 human hepatoblastoma-derived (Hep G2) cells. J Clin Endocrinol Metab.
- 511 1995;80:1283–9.
- 512 28. Ferroni P, Riondino S, Buonomo O, Palmirotta R, Guadagni F, Roselli M. Type 2
- 513 Diabetes and Breast Cancer: The Interplay between Impaired Glucose Metabolism and 514 Oxidant Stress. Oxid Med Cell Longev. 2015;2015:183928.
- 515 29. Hatoum D, McGowan EM. Recent advances in the use of metformin: can treating 516 diabetes prevent breast cancer? BioMed Res Int. 2015;2015:548436.
- 30. Faria J, Negalha G, Azevedo A, Martel F. Metformin and Breast Cancer: Molecular
 Targets. J Mammary Gland Biol Neoplasia. 2019;24:111–23.
- 31. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin.
 Diabetologia. 2017;60:1577–85.
- 32. Tang GH, Satkunam M, Pond GR, Steinberg GR, Blandino G, Schunemann HJ, et
- al. Association of Metformin with Breast Cancer Incidence and Mortality in Patients with
- 523 Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis. Cancer
- 524 Epidemiol Biomarkers Prev. Philadelphia: Amer Assoc Cancer Research; 2018;27:627– 525 35.
- 526 33. Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM.
- 527 Obesity and adverse breast cancer risk and outcome: Mechanistic insights and
- 528 strategies for intervention: Breast Cancer, Inflammation, and Obesity. CA Cancer J Clin. 529 2017:67:378–97.
- 34. Li P, Shan Z, Zhou L, Xie M, Bao W, Zhang Y, et al. MECHANISMS IN
- 531 ENDOCRINOLOGY: Parity and risk of type 2 diabetes: a systematic review and dose-532 response meta-analysis. Eur J Endocrinol. Bioscientifica Ltd; 2016;175:R231–45.
- 522 25 Hue D. Adehemowe CA. Ogundiron TO. Akong EE. Comphell O. Adeningkun A. et
- 35. Huo D, Adebamowo CA, Ogundiran TO, Akang EE, Campbell O, Adenipekun A, et
 al. Parity and breastfeeding are protective against breast cancer in Nigerian women. Br
 J Cancer. Nature Publishing Group; 2008;98:992–6.
- 36. Joung KH, Jeong J-W, Ku BJ. The Association between Type 2 Diabetes Mellitus
 and Women Cancer: The Epidemiological Evidences and Putative Mechanisms.
- 538 BioMed Res Int. 2015;2015:920618.
- 37. KIM J, LEE J, JANG SY, KIM C, CHOI Y, KIM A. Anticancer effect of metformin on
 estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines. Oncol Rep.
 2016;35:2553–60.
- 542 38. Zhang F, de Haan-Du J, Sidorenkov G, Landman GWD, Jalving M, Zhang Q, et al.
- 543 Type 2 Diabetes Mellitus and Clinicopathological Tumor Characteristics in Women
- 544 Diagnosed with Breast Cancer: A Systematic Review and Meta-Analysis. Cancers.
- 545 2021;13:4992.

Fanxiu Xiong

- 39. Dankner R, Boffetta P, Balicer RD, Boker LK, Sadeh M, Berlin A, et al. Time-
- 547 Dependent Risk of Cancer After a Diabetes Diagnosis in a Cohort of 2.3 Million Adults.
- 548 Am J Epidemiol. 2016;183:1098–106.
- 40. Harding JL, Shaw JE, Peeters A, Cartensen B, Magliano DJ. Cancer Risk Among
 People With Type 1 and Type 2 Diabetes: Disentangling True Associations, Detection
 Bias, and Reverse Causation. Diabetes Care. 2015;38:264–70.
- 41. Hemminki K, Li X, Sundquist J, Sundquist K. Risk of Cancer Following Hospitalization for Type 2 Diabetes. The Oncologist. 2010;15:548–55.
- 42. Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA, et al.
- 555 Type 2 Diabetes and Subsequent Incidence of Breast Cancer in the Nurses' Health 556 Study. Diabetes Care. 2003;26:1752–8.
- 43. Wang M, Hu R-Y, Wu H-B, Pan J, Gong W-W, Guo L-H, et al. Cancer risk among
 patients with type 2 diabetes mellitus: a population-based prospective study in China.
 Sci Rep. 2015;5:11503.
- 44. Attner B, Landin-Olsson M, Lithman T, Noreen D, Olsson H. Cancer among patients
 with diabetes, obesity and abnormal blood lipids: a population-based register study in
 Sweden. Cancer Causes Control. 2012;23:769–77.
- 45. Bosetti C, Rosato V, Polesel J, Levi F, Talamini R, Montella M, et al. Diabetes
 Mellitus and Cancer Risk in a Network of Case-Control Studies. Nutr Cancer.
 2012;64:643–51.
- 46. Tseng C-H. Diabetes and breast cancer in Taiwanese women: a detection bias? Eur
 J Clin Invest. 2014;44:910–7.
- 47. Weiderpass E, Gridley G, Persson I, Nyrén O, Ekbom A, Adami H-O. Risk of
 endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer.
 1997;71:360–3.
- 48. Wu AH, Yu MC, Tseng C-C, Stanczyk FZ, Pike MC. Diabetes and risk of breast cancer in Asian-American women. Carcinogenesis. 2007;28:1561–6.
- 49. Diabetes [Internet]. [cited 2022 Jul 11]. Available from: https://www.who.int/newsroom/fact-sheets/detail/diabetes
- 575

Fanxiu Xiong

Systematic Review

576 FIGURE LEGENDS

- 577 FIGURE 1. Flow diagram of study selection.
- 578 FIGURE 2. Forest plot of the association between diabetes and breast cancer risk.
- 579 FIGURE 3. Forest plots for the associations of diabetes with (A) estrogen receptor-
- positive breast cancer, (B) estrogen receptor-negative breast cancer, (C) triple-negative
- 581 breast cancer, and (D) human epidermal growth factor 2-positive breast cancer.
- 582

583 SUPPORTING INFORMATION

- 584 SUPPLEMENTARY FIGURE S1. Leave-one-out sensitivity meta-analyses of 70 studies
- assessing the association between diabetes and breast cancer risk.
- 586 SUPPLEMENTARY FIGURE S2. Cumulative temporal meta-analysis of 70 studies
- assessing the association between diabetes and breast cancer risk.
- 588 SUPPLEMENTARY FIGURE S3. Funnel plots of observed and imputed studies using
- trim-and-fill method for assessing publication bias among (A) all 70 studies, (B) 46
- 590 cohort studies, and (C) 24 case-control studies.



| which was n | nt doi: nttp o Risk ifie | d blyggaeen re | vi lelwiber the | 23.05.13.232 e author/fund | 89893; this v er. who has o | ersion posted iv pranted medRxiv |
|-----------------------------|------------------------------------|----------------|------------------------|-------------------------------|--------------------------------|-------------------------------------|
| (| ratio | limit | liAlltrigh | tszesarved. I | No-vense allo | wed without per |
| Adami 1991 | 0.896 | 0.766 | 1.048 | -1.375 | 0.169 | 1 |
| Attner 2012 | 1.185 | 0.994 | 1.414 | 1.889 | 0.059 | |
| Baron 2001 | 1.105 | 0.963 | 1.268 | 1.429 | 0.153 | |
| Beji 2007 | 3.456 | 2.076 | 5.752 | 4.769 | 0.000 | |
| Bergkvist 1988 | 0.896 | 0.425 | 1.887 | -0.289 | 0.772 | < |
| Bosetti 2012 | 1.051 | 1 343 | 2 236 | 2.500 | 0.012 | |
| Bowker 2011 | 1.000 | 0.907 | 1.103 | 0.000 | 1.000 | |
| Bronsveld 2017 | 1.010 | 0.934 | 1.092 | 0.250 | 0.803 | |
| Carstensen 2012 | 1.051 | 1.011 | 1.093 | 2.500 | 0.012 | |
| Chlebowski 2012 | 0.990 | 0.863 | 1.136 | -0.143 | 0.886 | |
| Crispo 2017 | 2.460 | 0.800 | 1.170 | 3 103 | 1.000 | |
| Dankner 2016 | 1.994 | 1.955 | 2.033 | 69.000 | 0.000 | |
| Fang 2018 | 1.127 | 1.002 | 1.268 | 2.000 | 0.046 | |
| Garcia-Esquinas 2016 | 1.094 | 0.815 | 1.468 | 0.600 | 0.549 | |
| Gini 2016 | 1.139 | 0.993 | 1.306 | 1.857 | 0.063 | |
| Gong 2016 Goodman 1997 | 1.020 | 0.925 | 1.125 | 0.400 | 0.689 | |
| Harding 2015 | 1 127 | 1 106 | 1 150 | 12 000 | 0.004 | |
| He 2018 | 1.284 | 0.885 | 1.863 | 1.316 | 0.188 | |
| Hemminki 2010 | 1.363 | 1.286 | 1.446 | 10.333 | 0.000 | |
| Hjalgrim 1997 | 0.698 | 0.312 | 1.558 | -0.878 | 0.380 | < |
| Hsieh 2014 | 0.411 | 0.365 | 0.462 | -14.833 | 0.000 | Ĕ. |
| | 0.627 | 1 263 | 1.540 | -0.594 | 0.553 | |
| Juna 2013 | 0.970 | 0.830 | 1.135 | -0.375 | 0.708 | |
| Khan 2006 | 1.271 | 0.516 | 3.132 | 0.522 | 0.602 | |
| Kuriki 2007 | 1.162 | 0.901 | 1.499 | 1.154 | 0.249 | |
| Lambe 2011 | 1.150 | 0.964 | 1.372 | 1.556 | 0.120 | |
| Lavecchia 1994 | 0.803 | 0.622 | 1.035 | -1.692 | 0.091 | |
| Magliano 2012 | 0.861 | 0.527 | 1.405 | -0.600 | 0.549 | |
| Maskarinec 2017 | 0.951 | 0.571 | 1.583 | -0.192 | 0.848 | - |
| Maskarinec Ice 2019 | 1.010 | 0.682 | 1.495 | 0.050 | 0.960 | |
| Maskarinec Ja 2019 | 1.083 | 1.002 | 1.172 | 2.000 | 0.046 | |
| Mourouti 2013 | 1.174 | 0.502 | 3 705 | 2.286 | 0.022 | |
| Nakamura 2013 | 1.150 | 0.302 | 2.834 | 0.304 | 0.761 | < |
| Ogunleye 2009 | 1.051 | 0.753 | 1.467 | 0.294 | 0.769 | ľ |
| Omara 1985 | 1.185 | 0.901 | 1.560 | 1.214 | 0.225 | |
| Onitilo 2014 | 1.073 | 0.899 | 1.279 | 0.778 | 0.437 | |
| Paimer 2017 Pap 2018 | 1.100 | 0.994 | 1.414 | 1.889 | 0.059 | |
| Park 2021 | 0.990 | 0.863 | 1.136 | -0.143 | 0.886 | |
| Rapp 2006 | 1.377 | 1.026 | 1.848 | 2.133 | 0.033 | |
| Rastad 2019 | 0.932 | 0.539 | 1.614 | -0.250 | 0.803 | I — |
| Redaniel 2012 | 1.116 | 0.973 | 1.280 | 1.571 | 0.116 | |
| Reeves 2012 Repport 2020 | 1.209 | 0.833 | 1.755 | 1.000 | 0.317 | |
| Rollison 2008 | 1.062 | 0.856 | 1.317 | 0.545 | 0.585 | |
| Ronco post 2012 | 1.632 | 1.000 | 2.664 | 1.960 | 0.050 | |
| Ronco pre 2012 | 1.310 | 0.586 | 2.926 | 0.659 | 0.510 | 1 |
| Salinas-Martínez 2014 | 2.586 | 1.615 | 4.139 | 3.958 | 0.000 | |
| Sanderson 2010 | 1.010 | 0.847 | 1.205 | 0.111 | 0.912 | |
| Sellers 2007 | 1.616 | 0.990 | 2.638 | 1,920 | 0.055 | |
| Steenland 1995 | 1.405 | 0.708 | 2.790 | 0.971 | 0.331 | |
| Tabassum 2016 | 2.974 | 1.358 | 6.514 | 2.725 | 0.006 | |
| Talamini 1997 | 1.405 | 1.047 | 1.885 | 2.267 | 0.023 | |
| Vatseba 2019 | 3.287 | 2.598 | 4.159 | 9.917 | 0.000 | |
| Wang cc 2015 | 1.010 | 0.765 | 1 114 | 0 200 | 0.841 | |
| Wang cs 2015 | 3.490 | 0.957 | 12.725 | 1.894 | 0.058 | |
| Weiderpass 1997 | 1.297 | 1.199 | 1.403 | 6.500 | 0.000 | |
| Weiss 1999 | 1.127 | 0.691 | 1.840 | 0.480 | 0.631 | |
| Wideroff 1997 | 1.105 | 1.063 | 1.149 | 5.000 | 0.000 | |
| Vvu 2007 Yeh 2012 | 1.716 | 0.608 | 2.540 | 0.241 | 0.007 | |
| Zhang 2012 | 2.203 | 1.579 | 3.075 | 4.647 | 0.000 | |
| | 1.195 | 1.106 | 1.292 | 4.489 | 0.000 | |



Risk ratio and 95% CI May 15, 2023. The copyright holder for this preprint iv a license to display the preprint in perpetuity. Irmission. Study name Statistics for each study

(A)

Statistics for each study

Risk ratio and 95% CI

Study name med Rxiv preprint doi: https://doi.org/10.1101/2023.05.13.23289893; this version posted May 15, 2023. The copyright holder for this preprint (which was not certified by peer review) is the authomore, who has granted medRxiv a license to display the preprint in perpetuity. ratio All rights reserview it or review it or review it or review it or review.

| AlSaeed 2017 | 0.720 | 0.222 | 2.338 | -0.547 | 0.585 | k |
|----------------------|-------|-------|-------|--------|-------|-------------|
| Chlebowski 2012 | 1.110 | 0.858 | 1.436 | 0.794 | 0.427 | |
| Crispo 2017 | 2.820 | 1.691 | 4.703 | 3.973 | 0.000 | |
| Garcia-Esquinas 2016 | 0.940 | 0.682 | 1.295 | -0.379 | 0.705 | + |
| Lipscombe 2015 | 1.160 | 1.055 | 1.276 | 3.058 | 0.002 | |
| Maskarinec 2017 | 1.060 | 0.951 | 1.181 | 1.054 | 0.292 | + ⊷_ |
| Maskarinec 2019 | 0.690 | 0.252 | 1.887 | -0.723 | 0.470 | K I |
| Michels 2003 | 1.220 | 1.011 | 1.472 | 2.077 | 0.038 | |
| Palmer 2017 | 1.020 | 0.797 | 1.305 | 0.157 | 0.875 | |
| Park 2021 | 0.920 | 0.785 | 1.078 | -1.034 | 0.301 | |
| Reeves 2012 | 1.350 | 0.882 | 2.065 | 1.383 | 0.167 | |
| Rollison 2008 | 1.080 | 0.840 | 1.389 | 0.599 | 0.549 | |
| Sanderson 2019 | 0.982 | 0.790 | 1.220 | -0.164 | 0.870 | |
| | 1.093 | 0.996 | 1.199 | 1.874 | 0.061 | |
| | | | | | | 0.5 1 |

| ſ | D | ۱. |
|----|---|----|
| L | D | 1 |
| ١. | | |

| Study name | | Statis | tics for ea | ach study | | Risk ratio and 95% Cl |
|----------------------|---------------|----------------|----------------|-----------|---------|--|
| | Risk ratio | Lower limit | Upper limit | Z-Value | p-Value | |
| Chlebowski 2012 | 1.780 | 1.048 | 3.024 | 2.133 | 0.033 | |
| Crispo 2017 | 2.085 | 0.786 | 5.533 | 1.476 | 0.140 | |
| Garcia-Esquinas 2016 | 1.410 | 0.531 | 3.745 | 0.689 | 0.491 | — — I — — — — — — — — — — — — — — — — — — — |
| Lipscombe 2015 | 1.260 | 0.983 | 1.615 | 1.825 | 0.068 | |
| Maskarinec 2017 | 1.020 | 0.825 | 1.262 | 0.183 | 0.855 | — |
| Maskarinec 2019 | 1.220 | 0.379 | 3.923 | 0.334 | 0.739 | └───→ |
| Michels 2003 | 1.130 | 0.789 | 1.618 | 0.667 | 0.505 | |
| Palmer 2017 | 1.420 | 1.019 | 1.979 | 2.071 | 0.038 | |
| Park 2021 | 1.070 | 0.749 | 1.528 | 0.372 | 0.710 | |
| Rollison 2008 | 0.960 | 0.612 | 1.505 | -0.178 | 0.859 | |
| Sanderson 2019 | 1.039 | 0.726 | 1.488 | 0.209 | 0.835 | |
| | 1.161 | 1.040 | 1.297 | 2.656 | 0.008 | |
| | | | | | | 0.5 1 2 |

(C)

| Study name | | Statis | tics for e | ach study | | R | Risk ratio and 9 | 5% CI |
|----------------------|---------------|----------------|----------------|-----------|---------|--------------|------------------|-------|
| | Risk ratio | Lower limit | Upper limit | Z-Value | p-Value | | | |
| Chlebowski 2012 | 0.760 | 0.338 | 1.709 | -0.664 | 0.507 | K | + + | |
| Crispo 2017 | 3.040 | 1.239 | 7.461 | 2.427 | 0.015 | | | |
| Garcia-Esquinas 2016 | 0.830 | 0.376 | 1.831 | -0.461 | 0.644 | | | |
| | 1.215 | 0.523 | 2.823 | 0.453 | 0.651 | | | |
| | | | | | | 0.5 | 1 | |

(D)

| Study name | | Statis | tics for e | ach study | | Risk ratio and 95% CI | |
|----------------------|---------------|----------------|----------------|-----------|---------|--|---|
| | Risk ratio | Lower limit | Upper limit | Z-Value | p-Value | | |
| Chlebowski 2012 | 1.780 | 1.048 | 3.024 | 2.133 | 0.033 | +> | |
| Crispo 2017 | 1.080 | 0.270 | 4.315 | 0.109 | 0.913 | < | |
| Garcia-Esquinas 2016 | 2.250 | 1.220 | 4.150 | 2.597 | 0.009 | | |
| Michels 2003 | 0.980 | 0.724 | 1.327 | -0.131 | 0.896 | —————————————————————————————————————— | |
| Park 2021 | 1.400 | 0.904 | 2.169 | 1.507 | 0.132 | · · · · · · · · · · · · · · · · · · · | |
| | 1.408 | 1.010 | 1.962 | 2.021 | 0.043 | | |
| | | | | | | 0.5 1 2 | 2 |

| Study ID | Study design | Country of study | N participants | Age (years) | Time frame or follow- up | DM identification | BCa identification | Adjusted for BMI | Quality |
|----------------------------------|------------------|------------------|-------------------|----------------|---------------------------------|----------------------|-----------------------|---------------------|--------------|
| Omara 1985 ¹ | Case- control | US | 9,165 | 30-89 | 1957-1965 | Medical records | Medical records | No | Medium |
| Bergkvist 1988 ² | Case- control | Sweden | 1,975 | ≥35 | 1977-1980 | Self-report | Medical records | No | Low |
| Adami 1991 ³ | Cohort | Sweden | 27,862 | ≥20 | Mean 5.2 years [†] | Medical records | Medical records | No | Low All righ |
| Lavecchia 1994 ⁴ | Case- control | Italy | 8,116 | <75 | 1983-1985 | Self-report | Medical records | No | Medium |
| Steenland 1995 ⁵ | Cohort | US | 7,204 | 25-74 | Mean 7.7 years | Self-report | Medical records | Yes | Low Z |
| Goodman 1997 ⁶ | Cohort | Japan | 22,200 | NA | Mean 8.3 years | Self-report | Medical records | No | Low allow |
| Hjalgrim 1997 ⁷ | Cohort | Denmark | 402 | NA | Mean 10.1 years [†] | Medical records | Medical records | No | Medium |
| Talamini 1997 ⁸ | Case- control | Italy | 5,157 | Median 55 | 1991-1994 | Self-report | Medical records | Yes | High High |
| Wideroff 1997 ⁹ | Cohort | Denmark | 55,010 | Median 69 | 1977-1993 | Medical records | Medical records | No | Medium |
| Weiderpass 1997 ¹⁰ | Cohort | Sweden | 80,005 | Mean 64.2 | Mean 6.7 years | Medical records | Medical records | No | Low |
| Weiss 1999 ¹¹ | Case- control | US | 4,163 | 20-54 | 1990-1992 | Self-report | Medical records | Yes | Medium |
| Baron 2001 ¹² | Case- control | US | 17,515 | 50-75 | 1990-1994 | Self-report | Medical records | Yes | Medium |
| Michels 2003 ¹³ | Cohort | US | 116,488 | 30 –55 | Mean 20.3 | Medical | Self-report | Yes | Medium |

TABLE 1. Characteristics of studies included in the systematic review

| Study ID | Study design | Country of study | N participants | Age (years) | Time frame or follow- up | DM identification | BCa identification | Adjusted for BMI | Quality |
|---------------------------------|------------------|------------------|-------------------|----------------|---------------------------------|--------------------------------------|-----------------------|---------------------|---------|
| | | | | | years [†] | records | | | |
| Jee 2005 ¹⁴ | Cohort | South Korea | 468,615 | Mean 49.6 | Up to 10 years | Self-report or Medical records | Medical records | No | Medium |
| Khan 2006 ¹⁵ | Cohort | Japan | 33,503 | 40-79 | Mean 8.0 years [†] | Self-report | Medical records | Yes | Medium |
| Inoue 2006 ¹⁶ | Cohort | Japan | 51,223 | Mean 51.8 | 1990-2003 | Self-report | Medical records | Yes | Medium |
| Rapp 2006 ¹⁷ | Cohort | Austria | 77,228 | Mean 43 | Mean 8.6 years | Medical records | Medical records | Yes | High |
| Wu 2007 ¹⁸ | Case- control | US | 2,396 | 25-74 | 1995-2001 | Self-report | Medical records | Yes | High |
| Sellers 2007 ¹⁹ | Cohort | US | 6,130 | >18 | Mean 40.2 years [†] | Self-report | Self-report | Yes | Low |
| Beji 2007 ²⁰ | Case- control | Turkish | 1,455 | Median 56 | 2002-2003 | Self-report | Medical records | Yes | Low |
| Kuriki 2007 ²¹ | Case- control | Japan | 39,900 | 40–80 | Starting 1988 | Self-report | Medical records | Yes | Medium |
| Rollison 2008 ²² | Case- control | US | 4,847 | Mean 55.7 | 1999-2004 | Self-report | Medical records | Yes | Medium |
| Ogunleye 2009 ²³ | Cohort | UK | 13,416 | Mean 62 | 1993-2004 | Medical records | Medical records | No | Medium |
| Sanderson 2010 ²⁴ | Case- control | Mexico | 1,169 | 30-79 | 2003-2008 | Medical records | Medical records | No | Medium |
| Chodick 2010 ²⁵ | Cohort | Israel | 47,682 | Mean 62 | Mean 8 years | Medical records | Medical records | Yes | Medium |

| Study ID | Study design | Country of study | N participants | Age (years) | Time frame or follow- up | DM identification | BCa identification | Adjusted for BMI | Quality |
|----------------------------------|------------------|-----------------------|-------------------|----------------|--------------------------------|----------------------|-----------------------|---------------------|---------|
| Hemminki 2010 ²⁶ | Cohort | Sweden | 62,563 | >39 | Median 15 years | Medical records | Medical records | No | Medium |
| Bowker 2011 ²⁷ | Cohort | Canada | 169,012 | Mean 61.8 | Mean 4.4 years | Medical records | Medical records | No | Medium |
| Lambe 2011 ²⁸ | Cohort | Sweden | 230,737 | Mean 46.6 | Mean 11.7 years | Medical records | Medical records | No | Medium |
| Ronco 2012 ²⁹ | Case- control | Uruguay | 750 | >18 | 2004-2010 | Self-report | Medical records | No | Medium |
| Ronco 2012 ³⁰ | Case- control | Uruguay | 912 | 23-69 | 2004-2009 | Self-report | Medical records | Yes | Medium |
| Reeves 2012 ³¹ | Cohort | US | 8,956 | >65 | 1986-2009 | Self-report | Medical records | Yes | Medium |
| Yeh 2012 ³² | Cohort | US | 10,467 | ≥30 | 1989-2006 | Self-report | Medical records | Yes | Medium |
| Chlebowski 2012 ³³ | Cohort | US | 68,019 | 63.9 | Mean 11.8 years | Self-report | Medical records | Yes | High |
| Zhang 2012 ³⁴ | Cohort | China | 4,155 | Mean 61.1 | Mean 9.1 years [†] | Medical records | Medical records | No | Low |
| Magliano 2012 ³⁵ | Cohort | Australia | 3,315 | ≥45 | Mean 11.0 years | Medical records | Medical records | No | Low |
| Bosetti 2012 ³⁶ | Case- control | Italy and Switzerland | 6,426 | Median 50 | 1991-2009 | Self-report | Medical records | Yes | Medium |
| Attner 2012 ³⁷ | Case- control | Sweden | 23,566 | 45-84 | Up to 10 years | Medical records | Medical records | No | Medium |
| Redaniel | Cohort | UK | 82,867 | >35 | 1987-2007 | Medical | Medical | Yes | High |

| Study ID | Study design | Country of study | N participants | Age (years) | Time frame or follow- up | DM identification | BCa identification | Adjusted for BMI | Quality |
|--|----------------------------------|------------------|-------------------|-----------------|---------------------------------|--------------------------------------|-----------------------|---------------------|---------|
| 2012 ³⁸ | | | | | | records | records | | |
| Carstensen 2012 ³⁹ | Cohort | Danish | 260,804 | 65-75 | 1995-2009 | Medical records | Medical records | No | Medium |
| Wang 2013 ⁴⁰ | Case- control | China | 492 | Mean 49.9 | In 2008 | Self-report | Self-report | Yes | Medium |
| Jung 2013 ⁴¹ | Case- control | South Korea | 5,060 | Mean 48 | 2001-2007 | Self-report | Medical records | No | Low |
| Nakamura 2013 ⁴² | Cohort | Japan | 16,547 | >35 | Mean 14.0 years [†] | Self-report | Medical records | Yes | Medium |
| Mourouti 2013 ⁴³ | Case- control | Greece | 500 | Mean 56 | 2010-2012 | Medical records | Medical records | Yes | Medium |
| Salinas- Martínez 2014 ⁴⁴ | Case- control | Mexico | 646 | NA [§] | 2011-2013 | Self-report or Medical records | Medical records | No | Low |
| Onitilo 2014 ⁴⁵ | Cohort | US | 31,769 | >30 | 1995-2009 | Medical records | Medical records | Yes | Medium |
| Hsieh 2014 ⁴⁶ | Cohort | China | 18,563 | >20 | 2000-2010 | Medical records | Medical records | Yes | Low |
| Lipscombe 2015 ⁴⁷ | cross- sectional [‡] | Canada | 38,407 | 20–105 | 2007-2012 | Medical records | Medical records | No | |
| Wang 2015 ⁴⁸ | Case- control | China | 129 | Mean 53 | 2011-2013 | Medical records | Self-report | No | Medium |
| Wang 2015 ⁴⁹ | Cohort | China | 163,449 | 59.4 | 2007-2013 | Medical records | Medical records | No | Medium |
| Liaw 2015 ⁵⁰ | Cohort | China | 10,827,079 | Mean 60.2 | 2004-2010 | Medical records | Medical records | No | Medium |

| Study ID | Study design | Country of study | N participants | Age (years) | Time frame or follow- up | DM identification | BCa identification | Adjusted for BMI | Quality |
|---|----------------------------------|------------------|-------------------|-----------------|---------------------------------|--------------------------------------|-----------------------|---------------------|--------------|
| Harding 2015 ⁵¹ | Cohort | Australia | 408,426 | Median 60.4 | Median 5.8 years | Medical records | Medical records | Yes | Medium |
| Gong 2016 ⁵² | Cohort | US | 145,826 | 50-79 | 1993-2015 | Self-report | Medical records | Yes | High |
| Tabassum 2016 ⁵³ | Case- control | Pakistan | 400 | 30-70 | 2014-2015 | Self-report | Medical records | No | Low _≧ |
| Dankner 2016 ⁵⁴ | Cohort | Israel | 1,152,122 | 21-89 | 2002-2012 | Medical records | Medical records | No | تو Medium |
| Garcia- Esquinas 2016 ⁵⁵ | Case- control | Spanish | 2010 | 20-85 | 2008-2013 | Self-report | Medical records | Yes | Medium |
| Gini 2016 ⁵⁶ | Cohort | Italy | 14,420 | 40-84 | Median 3.7 years | Medical records | Medical records | No | Medium® |
| Palmer 2017 ⁵⁷ | Cohort | US | 54,337 | 21-69 | Mean 15.6 years [†] | Self-report | Self-report | Yes | چ Medium |
| Maskarinec 2017 ⁵⁸ | Cohort | US | 103,721 | 45-75 | Mean 14.8 years [†] | Self-report | Medical records | Yes | Medium |
| AlSaeed 2017 ⁵⁹ | cross- sectional [‡] | Saudi Arabia | 110 | Mean 47 | 2000-2006 | Medical records | Medical records | Yes | rmission. |
| Crispo 2017 ⁶⁰ | Case- control | Italy | 1,149 | NA [§] | 2009-2013 | Self-report or Medical records | Medical records | Yes | Medium |
| Bronsveld 2017 ⁶¹ | Cohort | UK | 295,996 | Median 64 | Mean 5.3 years [†] | Medical records | Medical records | No | Low |
| Fang 2018 ⁶² | Cohort | China | 27,200 | Mean 60 | Mean 6.65 years | Medical records | Medical records | No | Medium |
| | | | | | jouro | | | | |

| Study ID | Study design | Country of study | N participants | Age (years) | Time frame or follow- up | DM identification | BCa identification | Adjusted for BMI | Quality |
|--|--|---|---|--|--|---------------------------------------|--|---------------------|------------|
| an 2018 ⁶³ | Cohort | China | 300,060 | 30-79 | 2004-2013 | Medical records | Medical records | Yes | High |
| le 2018 ⁶⁴ | Cohort | China | 379,521 | ≥18 | 2009-2014 | Medical records | Medical records | No | Low |
| astad 2019 ⁶⁵ | Cohort | US | 7,630 | 45-64 | 1990-1998 | Medical records | Self-report | Yes | Mediur |
| anderson 019 ⁶⁶ | Cohort | US | 25,366 | 40-49 | Mean 7.0 years [†] | Self-report | Medical records | Yes | Mediur |
| laskarinec 019 ⁶⁷ | Cohort | Japan | 29,818 | 50.9 | Mean 27.6 years | Self-report | Medical records | Yes | Mediur |
| atseba 019 ⁶⁸ | Cohort | lvano- Frankivsk | 395,767 | NA [§] | 2012-2017 | Medical records | Medical records | No | Low |
| laskarinec 019 ⁶⁹ | Cohort | Iceland | 9,606 | Mean 53.2 | Mean 28.4 years | Medical records | Medical records | Yes | High |
| ennert 020 ⁷⁰ | Case- control | Israel | 10164 | 62.2 | Starting 1998 | Medical records | Medical records | No | Mediur |
| jornsdottir 020 ⁷¹ | Cohort | Sweden | 1248114 | 65.2 | Median 6.6 years | Medical records | Medical records | No | Mediur |
| ark 2021 ⁷² | Cohort | US | 44541 | 35-74 | Median 8.6 years | Medical records | Medical records | Yes | High |
| 3MI, body mass If the cohort stud of follow-up years Lipscombe 2015 studies was not a Unreported. | index; DM, d dy did not pro s by the num 5 and AlSaee assessed due | iabetes mellitus ovide the mean ber of participa d 2017 studied e to their cross- | s; NA, not availa or median lengt nts. the molecular e sectional design | ble; UK, the h of follow-u xpression c | e United Kingdo up, the mean fo of breast cancer | m; US, the Unite llow-up length wa | d States. as calculated by c osis. The risk of b | dividing the to | otal lengt |

| Subgroup | N studies | Summary estimate | 95% Cl | ^{l²} | P |
|-----------------------|-----------|------------------|-----------|--------------------------|--------|
| All studies | 70 | 1.20 | 1.11-1.29 | 97.9% | <0.001 |
| Study quality | | | | | |
| High | 9 | 1.12 | 1.02-1.22 | 53.0% | 0.03 |
| Medium | 45 | 1.15 | 1.05-1.27 | 98.4% | <0.001 |
| Low | 16 | 1.42 | 1.08-1.86 | 96.6% | <0.001 |
| Study design | | | | | |
| Cohort | 46 | 1.15 | 1.05-1.27 | 98.6% | <0.001 |
| Case-control | 24 | 1.26 | 1.13-1.40 | 73.1% | <0.001 |
| Study region | | | | | |
| Asia | 23 | 1.34 | 1.11-1.63 | 99.1% | <0.001 |
| Americas | 23 | 1.10 | 1.03-1.17 | 40.8% | 0.02 |
| Europe | 21 | 1.13 | 1.06-1.21 | 83.4% | <0.001 |
| Australia | 3 | 1.15 | 0.99-1.33 | 32.0% | 0.23 |
| Year of publication | | | | | |
| Before 2012 | 28 | 1.18 | 1.09-1.26 | 77.6% | <0.001 |
| In/after 2012 | 42 | 1.20 | 1.08-1.33 | 98.7% | <0.001 |
| DM ascertainment | | | | | |
| Self-report | 30 | 1.18 | 1.09-1.29 | 62.0% | <0.001 |
| Medical records | 37 | 1.14 | 1.03-1.26 | 98.9% | <0.001 |
| Both | 3 | 2.00 | 1.33-3.01 | 68.7% | 0.04 |
| Adjustment for BMI | | | | | |
| No | 31 | 1.21 | 1.08-1.35 | 98.9% | <0.001 |
| Yes | 39 | 1.19 | 1.06-1.32 | 89.7% | <0.001 |
| Adjustment for parity | | | | | |
| No | 56 | 1.15 | 1.06-1.26 | 98.3% | <0.001 |
| | | | | | |

TABLE 2. Summary estimates of the associations between diabetes and breast cancer risk across subgroups defined by study quality, study design, study region, diabetes ascertainment, adjustment for BMI, year of publication, and menopausal status.

| Yes | 14 | 1.39 | 1.18-1.62 | 79.7% | <0.001 |
|--------------------------------|----|------|-----------|-------|--------|
| Menopausal status [†] | | | | | |
| Pre | 15 | 0.95 | 0.85-1.05 | 0.00% | 0.78 |
| Post | 31 | 1.12 | 1.07-1.17 | 65.5% | <0.001 |

Abbreviations: BMI, body mass index; CI, confidence interval; DM, diabetes mellitus.

[†]The numbers of studies in the subgroups defined by menopausal status do not sum up to 70 because only a subset of the studies assessed pre- and post-menopausal breast cancer separately.

References

- 1. O'Mara BA, Byers T, Schoenfeld E. Diabetes mellitus and cancer risk: A multisite case-control study. *J Chronic Dis*. 1985;38(5):435-441. doi:10.1016/0021-9681(85)90139-0
- 2. Bergkvist L, Persson I, Adami HO, Schairer C. Risk Factors for Breast and Endometrial Cancer in a Cohort of Women Treated with Menopausal Oestrogens. *Int J Epidemiol*. 1988;17(4):732-737. doi:10.1093/ije/17.4.732
- 3. Adami HO, McLaughlin J, Ekbom A, et al. Cancer risk in patients with diabetes mellitus. *Cancer Causes Control*. 1991;2(5):307-314. doi:10.1007/BF00051670
- 4. La Vecchia C, Negri E, Franceschi S, D'Avanzo B, Boyle P. A case-control study of diabetes mellitus and cancer risk. *Br J Cancer*. 1994;70(5):950-953. doi:10.1038/bjc.1994.427
- 5. Steenland K, Nowlin S, Palu S. Cancer incidence in the National Health and Nutrition Survey I. Follow-up data: diabetes, cholesterol, pulse and physical activity. *Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol.* 1995;4(8):807-811.
- 6. Goodman MT, Cologne JB, Moriwaki H, Vaeth M, Mabuchi K. Risk Factors for Primary Breast Cancer in Japan: 8-Year Follow-Up of Atomic Bomb Survivors. *Prev Med.* 1997;26(1):144-153. doi:10.1006/pmed.1996.9979
- Hjalgrim H, Frisch M, Ekbom A, Kyvik KO, Melbye M, Green A. Cancer and diabetes a follow-up study of two populationbased cohorts of diabetic patients. *J Intern Med.* 2007;241(6):471-475. doi:10.1111/j.1365-2796.1997.tb00004.x
- 8. Talamini R, Franceschi S, Favero A, Negri E, Parazzini F, La Vecchia C. Selected medical conditions and risk of breast cancer. *Br J Cancer*. 1997;75(11):1699-1703. doi:10.1038/bjc.1997.289
- 9. Wideroff L, Gridley G, Chow WH, et al. Cancer Incidence in a Population-Based Cohort of Patients Hospitalized With Diabetes Mellitus in Denmark. *JNCI J Natl Cancer Inst*. 1997;89(18):1360-1365. doi:10.1093/jnci/89.18.1360

- Weiderpass E, Gridley G, Persson I, Nyrén O, Ekbom A, Adami HO. Risk of endometrial and breast cancer in patients with diabetes mellitus. *Int J Cancer*. 1997;71(3):360-363. doi:10.1002/(SICI)1097-0215(19970502)71:3<360::AID-IJC9>3.0.CO;2-W
- 11. Weiss HA, Brinton LA, Potischman NA, et al. Breast cancer risk in young women and history of selected medical conditions. *Int J Epidemiol*. 1999;28(5):816-823. doi:10.1093/ije/28.5.816
- 12. Baron JA, Weiderpass E, Newcomb PA, et al. Metabolic disorders and breast cancer risk (United States). :6.
- 13. Michels KB, Solomon CG, Hu FB, et al. Type 2 Diabetes and Subsequent Incidence of Breast Cancer in the Nurses' Health Study. *Diabetes Care*. 2003;26(6):1752-1758. doi:10.2337/diacare.26.6.1752
- 14. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting Serum Glucose Level and Cancer Risk in Korean Men and Women. :9.
- 15. Khan M, Mori M, Fujino Y, et al. Site-specific Cancer Risk Due to Diabetes Mellitus History: Evidence from the Japan Collaborative Cohort (JACC) Study. :8.
- 16. Inoue M. Diabetes Mellitus and the Risk of Cancer: Results From a Large-Scale Population-Based Cohort Study in Japan. *Arch Intern Med.* 2006;166(17):1871. doi:10.1001/archinte.166.17.1871
- 17. Rapp K, Schroeder J, Klenk J, et al. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. *Diabetologia*. 2006;49(5):945-952. doi:10.1007/s00125-006-0207-6
- 18. Wu AH, Yu MC, Tseng CC, Stanczyk FZ, Pike MC. Diabetes and risk of breast cancer in Asian-American women. *Carcinogenesis*. 2007;28(7):1561-1566. doi:10.1093/carcin/bgm081
- 19. Sellers TA, Jensen LE, Vierkant RA, et al. Association of diabetes with mammographic breast density and breast cancer in the Minnesota breast cancer family study. *Cancer Causes Control*. 2007;18(5):505-515. doi:10.1007/s10552-007-0128-9
- 20. Beji NK, Reis N. Risk factors for breast cancer in Turkish women: a hospital-based case?control study. *Eur J Cancer Care (Engl)*. 2007;16(2):178-184. doi:10.1111/j.1365-2354.2006.00711.x

- 21. Kuriki K, Hirose K, Tajima K. Diabetes and cancer risk for all and specific sites among Japanese men and women. *Eur J Cancer Prev.* 2007;16(1):83-89. doi:10.1097/01.cej.0000228404.37858.40
- 22. Rollison DE, Giuliano AR, Sellers TA, et al. Population-based Case-Control Study of Diabetes and Breast Cancer Risk in Hispanic and Non-Hispanic White Women Living in US Southwestern States. *Am J Epidemiol.* 2008;167(4):447-456. doi:10.1093/aje/kwm322
- 23. Ogunleye AA, Ogston SA, Morris AD, Evans JMM. A cohort study of the risk of cancer associated with type 2 diabetes. *Br J Cancer*. 2009;101(7):1199-1201. doi:10.1038/sj.bjc.6605240
- 24. Sanderson M, Peltz G, Perez A, et al. Diabetes, physical activity and breast cancer among Hispanic women. *Cancer Epidemiol.* 2010;34(5):556-561. doi:10.1016/j.canep.2010.06.001
- 25. Chodick G, Heymann AD, Rosenmann L, et al. Diabetes and risk of incident cancer: a large population-based cohort study in Israel. *Cancer Causes Control*. 2010;21(6):879-887. doi:10.1007/s10552-010-9515-8
- 26. Hemminki K, Li X, Sundquist J, Sundquist K. Risk of Cancer Following Hospitalization for Type 2 Diabetes. *The Oncologist*. 2010;15(6):548-555. doi:10.1634/theoncologist.2009-0300
- 27. Bowker SL, Richardson K, Marra CA, Johnson JA. Risk of Breast Cancer After Onset of Type 2 Diabetes. *Diabetes Care*. 2011;34(12):2542-2544. doi:10.2337/dc11-1199
- Lambe M, Wigertz A, Garmo H, Walldius G, Jungner I, Hammar N. Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer. *Cancer Causes Control*. 2011;22(8):1163-1171. doi:10.1007/s10552-011-9794-8
- 29. Ronco AL, Stefani ED, Deneo-Pellegrini H. Risk Factors for Premenopausal Breast Cancer: A Case-control Study in Uruguay. *Asian Pac J Cancer Prev.* 2012;13(6):2879-2886. doi:10.7314/APJCP.2012.13.6.2879
- Ronco AL, Stefani ED, Deneo-Pellegrini H, Quarneti A. Diabetes, Overweight and Risk of Postmenopausal Breast Cancer: A Case-Control Study in Uruguay. Asian Pac J Cancer Prev. 2012;13(1):139-146. doi:10.7314/APJCP.2012.13.1.139

- 31. Reeves KW, McLaughlin V, Fredman L, Ensrud K, Cauley JA. Components of metabolic syndrome and risk of breast cancer by prognostic features in the study of osteoporotic fractures cohort. *Cancer Causes Control.* 2012;23(8):1241-1251. doi:10.1007/s10552-012-0002-2
- 32. Yeh HC, Platz EA, Wang NY, Visvanathan K, Helzlsouer KJ, Brancati FL. A Prospective Study of the Associations Between Treated Diabetes and Cancer Outcomes. *Diabetes Care*. 2012;35(1):113-118. doi:10.2337/dc11-0255
- 33. Chlebowski RT, McTiernan A, Wactawski-Wende J, et al. Diabetes, Metformin, and Breast Cancer in Postmenopausal Women. *J Clin Oncol.* 2012;30(23):2844-2852. doi:10.1200/JCO.2011.39.7505
- 34. Zhang PH, Chen ZW, Lv D, et al. Increased risk of cancer in patients with type 2 diabetes mellitus: A retrospective cohort study in China. *BMC Public Health*. 2012;12(1):567. doi:10.1186/1471-2458-12-567
- Magliano DJ, Davis WA, Shaw JE, Bruce DG, Davis TME. Incidence and predictors of all-cause and site-specific cancer in type 2 diabetes: the Fremantle Diabetes Study. *Eur J Endocrinol.* 2012;167(4):589-599. doi:10.1530/EJE-12-0053
- 36. Bosetti C, Rosato V, Polesel J, et al. Diabetes Mellitus and Cancer Risk in a Network of Case-Control Studies. *Nutr Cancer*. 2012;64(5):643-651. doi:10.1080/01635581.2012.676141
- 37. Attner B, Landin-Olsson M, Lithman T, Noreen D, Olsson H. Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden. *Cancer Causes Control.* 2012;23(5):769-777. doi:10.1007/s10552-012-9946-5
- 38. Redaniel MTM, Jeffreys M, May MT, Ben-Shlomo Y, Martin RM. Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women. *Cancer Causes Control.* 2012;23(11):1785-1795. doi:10.1007/s10552-012-0057-0
- 39. Carstensen B, Witte DR, Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. *Diabetologia*. 2012;55(4):948-958. doi:10.1007/s00125-011-2381-4
- 40. Wang XL, Jia CX, Liu LY, Zhang Q, Li YY, Li L. Obesity, diabetes mellitus, and the risk of female breast cancer in Eastern China. *World J Surg Oncol.* 2013;11(1):71. doi:10.1186/1477-7819-11-71

- 41. Jung SJ, Song M, Choi JY, et al. Association of Selected Medical Conditions With Breast Cancer Risk in Korea. *J Prev Med Pub Health*. 2013;46(6):346-352. doi:10.3961/jpmph.2013.46.6.346
- 42. Nakamura K, Wada K, Tamai Y, et al. Diabetes mellitus and risk of cancer in Takayama: A population-based prospective cohort study in Japan. *Cancer Sci.* 2013;104(10):1362-1367. doi:10.1111/cas.12235
- 43. Mourouti N, Papavagelis C, Kontogianni MD, et al. Cardiometabolic Factors and Breast Cancer: A Case-Control Study in Women. *Open Hypertens J.* 2013;5(1):49-49. doi:10.2174/1876526201305010049
- 44. Salinas-Martínez AM, Flores-Cortés LI, Cardona-Chavarría JM, et al. Prediabetes, Diabetes, and Risk of Breast Cancer: A Case-Control Study. *Arch Med Res.* 2014;45(5):432-438. doi:10.1016/j.arcmed.2014.06.004
- 45. Onitilo AA, Stankowski RV, Berg RL, et al. Breast cancer incidence before and after diagnosis of type 2 diabetes mellitus in women: increased risk in the prediabetes phase. *Eur J Cancer Prev.* 2014;23(2):76-83. doi:10.1097/CEJ.0b013e32836162aa
- 46. Hsieh SH, Chiou WK, Wang MH, Lin JD. Association of Body Weight With the Risk for Malignancies in Hospitalized Patients With or Without Diabetes Mellitus in Taiwan. *J Investig Med*. 2014;62(1):37-42. doi:10.2310/JIM.00000000000004
- 47. Lipscombe LL, Fischer HD, Austin PC, et al. The association between diabetes and breast cancer stage at diagnosis: a population-based study. *Breast Cancer Res Treat*. 2015;150(3):613-620. doi:10.1007/s10549-015-3323-5
- 48. Wang M, Cheng N, Zheng S, et al. Metabolic syndrome and the risk of breast cancer among postmenopausal women in north-west China. *Climacteric*. 2015;18(6):852-858. doi:10.3109/13697137.2015.1071346
- 49. Wang M, Hu RY, Wu HB, et al. Cancer risk among patients with type 2 diabetes mellitus: a population-based prospective study in China. *Sci Rep.* 2015;5(1):11503. doi:10.1038/srep11503
- 50. Liaw YP, Ko PC, Jan SR, et al. Implications of Type1/2 Diabetes Mellitus in Breast Cancer Development: A General Female Population-based Cohort Study. *J Cancer*. 2015;6(8):734-739. doi:10.7150/jca.12197
- Harding JL, Shaw JE, Peeters A, Cartensen B, Magliano DJ. Cancer Risk Among People With Type 1 and Type 2 Diabetes: Disentangling True Associations, Detection Bias, and Reverse Causation. *Diabetes Care*. 2015;38(2):264-270. doi:10.2337/dc14-1996

- 52. Gong Z, Aragaki AK, Chlebowski RT, et al. Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: Results from the women's health initiative: Diabetes, Metformin and Incidence and Death from Invasive Cancer. *Int J Cancer*. 2016;138(8):1915-1927. doi:10.1002/ijc.29944
- 53. Tabassum I, Mahmood H, Faheem M. Type 2 Diabetes Mellitus as a Risk Factor for Female Breast Cancer in the Population of Northern Pakistan. :4.
- 54. Dankner R, Boffetta P, Balicer RD, et al. Time-Dependent Risk of Cancer After a Diabetes Diagnosis in a Cohort of 2.3 Million Adults. *Am J Epidemiol*. 2016;183(12):1098-1106. doi:10.1093/aje/kwv290
- 55. García-Esquinas E, Guinó E, Castaño-Vinyals G, et al. Association of diabetes and diabetes treatment with incidence of breast cancer. *Acta Diabetol.* 2016;53(1):99-107. doi:10.1007/s00592-015-0756-6
- 56. Gini A, Bidoli E, Zanier L, et al. Cancer among patients with type 2 diabetes mellitus: A population-based cohort study in northeastern Italy. *Cancer Epidemiol*. 2016;41:80-87. doi:10.1016/j.canep.2016.01.011
- Palmer JR, Castro-Webb N, Bertrand K, Bethea TN, Denis GV. Type II Diabetes and Incidence of Estrogen Receptor Negative Breast Cancer in African American Women. *Cancer Res.* 2017;77(22):6462-6469. doi:10.1158/0008-5472.CAN-17-1903
- 58. Maskarinec G, Jacobs S, Park SY, et al. Type II Diabetes, Obesity, and Breast Cancer Risk: The Multiethnic Cohort. *Cancer Epidemiol Biomarkers Prev.* 2017;26(6):854-861. doi:10.1158/1055-9965.EPI-16-0789
- 59. Alsaeed E, Albeeshi M, Alsari M, Alowaini F, Alsaawi A, Bahabri I. Obesity do not Affect Tumor Expression of Estrogen and. *KUWAIT Med J*. Published online 2017:5.
- Crispo A, Augustin LSA, Grimaldi M, et al. Risk Differences Between Prediabetes And Diabetes According To Breast Cancer Molecular Subtypes: DIABETES AND RISK OF BREAST CANCER SUBTYPES. *J Cell Physiol.* 2017;232(5):1144-1150. doi:10.1002/jcp.25579
- 61. Bronsveld HK, Peeters PJHL, de Groot MCH, de Boer A, Schmidt MK, De Bruin ML. Trends in breast cancer incidence among women with type-2 diabetes in British general practice. *Prim Care Diabetes*. 2017;11(4):373-382. doi:10.1016/j.pcd.2017.02.001

- 62. Fang Y, Zhang X, Xu H, et al. Cancer risk in Chinese diabetes patients: a retrospective cohort study based on management data. *Endocr Connect*. 2018;7(12):1415-1423. doi:10.1530/EC-18-0381
- 63. Pan XF, He M, Yu C, et al. Type 2 Diabetes and Risk of Incident Cancer in China: A Prospective Study Among 0.5 Million Chinese Adults. *Am J Epidemiol*.:12.
- 64. He X, Shi L, Wu J. Retrospective database analysis of cancer risk in patients with type 2 diabetes mellitus in China. *Curr Med Res Opin.* 2018;34(6):1089-1098. doi:10.1080/03007995.2017.1421527
- 65. Rastad H, Parsaeian M, Shirzad N, Mansournia MA, Yazdani K. Diabetes mellitus and cancer incidence: the Atherosclerosis Risk in Communities (ARIC) cohort study. *J Diabetes Metab Disord*. 2019;18(1):65-72. doi:10.1007/s40200-019-00391-5
- Sanderson M, Lipworth L, Shrubsole MJ, et al. Diabetes, obesity, and subsequent risk of postmenopausal breast cancer among white and black women in the Southern Community Cohort Study. *Cancer Causes Control*. 2019;30(5):425-433. doi:10.1007/s10552-019-01164-4
- 67. Maskarinec G, Sadakane A, Sugiyama H, Brenner A, Tatsukawa Y, Grant E. Type 2 diabetes, obesity, and breast cancer risk among Japanese women of the atomic bomb survivor cohort. *Cancer Epidemiol.* 2019;60:179-184. doi:10.1016/j.canep.2019.04.009
- 68. Vatseba TS, Sokolova LK. BREAST CANCER IN WOMEN WITH DIABETES MELLITUS TYPE 2. *World Med Biol.* 2019;15(68):030. doi:10.26724/2079-8334-2019-2-68-30-34
- 69. Maskarinec G, Haraldsdóttir Á, Einarsdóttir K, et al. Type 2 diabetes and obesity in midlife and breast cancer risk in the Reykjavik cohort. *Cancer Causes Control.* 2019;30(10):1057-1065. doi:10.1007/s10552-019-01213-y
- 70. Rennert G, Rennert HS, Gronich N, Pinchev M, Gruber SB. Use of metformin and risk of breast and colorectal cancer. *Diabetes Res Clin Pract.* 2020;165:108232. doi:10.1016/j.diabres.2020.108232
- 71. Bjornsdottir HH, Rawshani A, Rawshani A, et al. OPEN A national observation study. Sci Rep.:13.
- 72. Park YMM, Bookwalter DB, O'Brien KM, Jackson CL, Weinberg CR, Sandler DP. A prospective study of type 2 diabetes, metformin use, and risk of breast cancer. *Ann Oncol.* 2021;32(3):351-359. doi:10.1016/j.annonc.2020.12.008